Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) EBITDA (2018 - 2025)

Historic EBITDA for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to -$59.2 million.

  • Bicycle Therapeutics' EBITDA fell 1193.5% to -$59.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.9 million, marking a year-over-year decrease of 4560.59%. This contributed to the annual value of -$167.6 million for FY2024, which is 808.7% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' EBITDA stood at -$59.2 million, which was down 1193.5% from -$80.9 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year EBITDA high stood at -$14.4 million for Q3 2021, and its period low was -$80.9 million during Q2 2025.
  • Its 5-year average for EBITDA is -$38.3 million, with a median of -$39.4 million in 2023.
  • As far as peak fluctuations go, Bicycle Therapeutics' EBITDA skyrocketed by 3388.27% in 2024, and later tumbled by 13940.55% in 2025.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' EBITDA stood at -$18.2 million in 2021, then crashed by 65.2% to -$30.1 million in 2022, then plummeted by 76.92% to -$53.3 million in 2023, then rose by 8.89% to -$48.6 million in 2024, then dropped by 21.95% to -$59.2 million in 2025.
  • Its EBITDA was -$59.2 million in Q3 2025, compared to -$80.9 million in Q2 2025 and -$62.3 million in Q1 2025.